{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:17:16Z","timestamp":1777047436963,"version":"3.51.4"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n A study using Medicare data concluded that among patients aged 65 years or older, rivaroxaban had a less favorable benefit-harm profile compared with other non\u2013vitamin K oral anticoagulants (NOACs); however, it is unclear whether this finding persists in younger users.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare major extracranial bleeding (MEB), gastrointestinal bleeding (GIB), intracranial hemorrhage (ICH), and thromboembolic stroke in individuals aged younger than 65 years using non\u2013vitamin K oral anticoagulants (NOAC users) for nonvalvular atrial fibrillation (NVAF).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study using health care claims data between October 2010 and February 2022 in the FDA Sentinel System included standard dose NOAC (rivaroxaban, apixaban, and dabigatran) users with NVAF aged 21 to 64 years. Analyses conducted between December 2022 and August 2023.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Hazard ratios (HRs) and 95% CIs were estimated for each outcome (MEB, GIB, ICH, and thromboembolic stroke) in inverse probability of treatment-weighted pairwise comparisons: rivaroxaban vs apixaban, rivaroxaban vs dabigatran, and dabigatran vs apixaban.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of more than 173\u202f000 patients (mean [SD] age, 56.6 [7.23] years; 27.5% female; 72.5% male) were included across the 3 exposure cohorts. The number of NOAC users for each pairwise comparison were rivaroxaban (57\u202f932) vs apixaban (96\u202f057), rivaroxaban (57\u202f399) vs dabigatran (20\u202f188), and dabigatran (20\u202f163) vs apixaban (96\u202f668). Rivaroxaban was associated with higher risks of MEB and GIB compared with apixaban (MEB: HR, 1.91; 95% CI, 1.56-2.34; GIB: HR, 1.92, 95% CI, 1.54-2.39), while differences in thromboembolic stroke prevention were not significant (HR, 1.05; 95% CI, 0.77-1.44). Dabigatran was associated with higher thromboembolic stroke risk (rivaroxaban vs dabigatran: HR, 0.61; 95% CI, 0.39-0.94; dabigatran vs apixaban: HR, 1.74; 95% CI, 1.13-2.68).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that for patients aged younger than 65 years treated with NOACs for NVAF, apixaban was associated with the most favorable benefit-harm profile. While the results suggest that rivaroxaban may have provided greater stroke prevention than dabigatran, it was associated with higher bleeding risks than apixaban without additional stroke prevention. The higher thromboembolic stroke risks observed with dabigatran in younger patients suggest important age-related differences in effectiveness that warrant further investigation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.9082","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:30:21Z","timestamp":1777044621000},"page":"e269082","source":"Crossref","is-referenced-by-count":0,"title":["Stroke and Bleeding Risks With Non\u2013Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation"],"prefix":"10.1001","volume":"9","author":[{"given":"Marie C.","family":"Bradley","sequence":"first","affiliation":[{"name":"Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Kolonoski","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Graham","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"12","key":"zoi260281r1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi260281r2","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi260281r3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260281r4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260281r5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal safety of direct oral anticoagulants: a large population-based study.","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"issue":"13","key":"zoi260281r6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation.","volume":"68","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"zoi260281r7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/pds.4034","article-title":"Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.","volume":"25","author":"Gorst-Rasmussen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"zoi260281r8","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"key":"zoi260281r9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1125576","article-title":"Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: a nationwide cohort study.","volume":"14","author":"Grymonprez","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi260281r10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40256-016-0189-9","article-title":"Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D data.","volume":"17","author":"Hernandez","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"zoi260281r11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.amjcard.2017.07.092","article-title":"Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation.","volume":"120","author":"Hernandez","year":"2017","journal-title":"Am J Cardiol"},{"issue":"9","key":"zoi260281r12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/ijcp.12863","article-title":"Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a \u201creal-world\u201d observational study in the United States.","volume":"70","author":"Lip","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"8","key":"zoi260281r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20064","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding.","volume":"4","author":"Lip","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260281r14","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation.","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"issue":"4","key":"zoi260281r15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.003418","article-title":"Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation.","volume":"10","author":"Palamaner Subash Shantha","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"zoi260281r16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000365967","article-title":"Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.","volume":"90","author":"Sherid","year":"2014","journal-title":"Digestion"},{"issue":"5","key":"zoi260281r17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","article-title":"Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation.","volume":"132","author":"Graham","year":"2019","journal-title":"Am J Med"},{"issue":"4","key":"zoi260281r18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cpt.2979","article-title":"Six years of the US Food and Drug Administration\u2019s postmarket active risk identification and analysis system in the sentinel initiative: implications for real world evidence generation.","volume":"114","author":"Maro","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"zoi260281r21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10.","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"issue":"1","key":"zoi260281r22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"zoi260281r23","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research.","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"issue":"6","key":"zoi260281r24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use.","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"zoi260281r25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/pds.4550","article-title":"Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies-an application to the known association between angiotensin-converting enzyme inhibitors and angioedema.","volume":"27","author":"Panozzo","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"zoi260281r26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/pds.4563","article-title":"Early impact of the ICD-10-CM transition on selected health outcomes in 13 electronic health care databases in the United States.","volume":"27","author":"Panozzo","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi260281r28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"zoi260281r29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"zoi260281r30","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"zoi260281r31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models.","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi260281r32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1177\/0962280219869742","article-title":"Inverse probability weighted Cox model in multi-site studies without sharing individual-level data.","volume":"29","author":"Shu","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"zoi260281r33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1076029616631427","article-title":"Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications.","volume":"22","author":"Kubitza","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"zoi260281r35","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3390\/ijerph20043491","article-title":"Long-term outcomes after stroke in patients with atrial fibrillation: a single center study.","volume":"20","author":"Tracz","year":"2023","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"zoi260281r36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.33963\/v.kp.98356","article-title":"Oral anticoagulation therapy in atrial fibrillation patients at high risk of bleeding: clinical characteristics and treatment strategies based on data from the Polish multicenter register of atrial fibrillation (POL-AF).","volume":"82","author":"Maciorowska","year":"2024","journal-title":"Kardiol Pol"},{"key":"zoi260281r19","unstructured":"Rosati? K, Jorgensen? N, Soliz? M, Evans? BJ. Sentinel initiative principles and policies HIPAA and common rule compliance in the sentinel initiative. US Food and Drug Administration. February 1, 2018. Accessed March 4, 2026. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/communications\/publications-presentations\/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf"},{"key":"zoi260281r20","unstructured":"Office for Human Research Protections. 45 CFR \u00a746.102(l)(2). US Department of Health and Human Services. Accessed September 30, 2024. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html"},{"key":"zoi260281r27","unstructured":"Centers for Medicare & Medicaid Services. ICD-10 Files & News Archive. Accessed September 30, 2024. https:\/\/www.cms.gov\/medicare\/coding-billing\/icd-10-codes\/icd-10-cm-icd-10-pcs-gem-archive"},{"key":"zoi260281r34","unstructured":"US Food and Drug Administration. 2011 Meeting materials, Cardiovascular and Renal Drugs Advisory Committee. Accessed September 19, 2024. https:\/\/wayback.archive-it.org\/7993\/20170403223812\/https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm250287.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848140\/bradley_2026_oi_260281_1776441265.85818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:30:23Z","timestamp":1777044623000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.9082","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}